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Abstract
Background: Primary haemophagocytic lymphohistiocytosis (HLH) screening assays are increasingly being
performed in patients presenting with macrophage activation syndrome (MAS). The objective of this study was to
describe their diagnostic and prognostic relevance in children who had presented to paediatric rheumatology and
had undergone investigative work up for MAS.
Methods: Data was obtained retrospectively from an existing protein screening assay database and patient records.
Assays included: intracellular expression of perforin in CD56+ Natural Killer (NK) cells; CD107a Granule Release Assay
(GRA) in response to PHA in NK cells, or anti-CD3 stimulation of CD8 lymphocytes; in males Signal Lymphocyte
Activating Molecule Associated Protein (SAP), and X-linked Inhibitor of Apoptosis Protein (XIAP) expression. All
assays, requested by paediatric rheumatology, of children who had undergone investigative work up for MAS over
a 5-year period (2007–2011) were included.
Results: Twenty-one patients (15 female), median age 6.5 years (range 0.6–16) with follow-up of 16 months (range
1–51), were retrospectively identified. At presentation, 3/21 (14 %) fulfilled HLH-2004 diagnostic criteria. At least one
screening test result was available for all 21 patients; 7/21 (33 %) had at least one persistent screening test
abnormality. Of this group 4/7 (57 %) died or required haematopoietic stem cell transplantation (HSCT), compared
to 1/14 (7 %) with no screening test abnormality (p = 0.025). 3/21 (14 %) ultimately had a diagnosis of primary HLH
(two confirmed genetically; XIAP, familial HLH type 3, and one confirmed clinically). Of the six patients with
abnormal GRA 5/6 had negative routine genetic results.
Conclusions: Screening for primary HLH is warranted for children whose first rheumatological presentation is with
MAS, since overall 14 % had an eventual diagnosis of primary HLH. A persistently abnormal GRA in patients
presenting with MAS defines a high-risk group with poor outcome (mortality or HSCT), possibly due to as yet
unidentified genetic cause.
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Background
Haemophagocytic lymphohistiocytosis (HLH) is a life-
threatening condition characterised by excessive activation
of T cells and macrophages and extreme uncontrolled
inflammation driven by γ-interferon and other pro-
inflammatory cytokines [1]. Traditionally HLH is classi-
fied into primary (genetic/familial) or secondary forms
[2]. There is an increasing understanding of the genetic
and molecular basis of many primary forms of HLH,
summarised in Fig. 1 [3–10]. Secondary HLH may
occur in patients with infections such as Epstein Barr
Virus; haematological malignancies; metabolic condi-
tions; and a range of autoimmune and other inflamma-
tory conditions [2, 11]. When HLH is secondary to
these latter rheumatological conditions, it is usually re-
ferred to as macrophage activation syndrome (MAS)
[12]. This can be a severe and potentially fatal compli-
cation if not recognised early and treated aggressively.
In children, distinguishing between primary HLH and
MAS can be challenging particularly when the first pres-
entation of a rheumatological disorder is with MAS.
Whilst the clinical features (including in some cases in-
fectious triggers) may be identical for both primary HLH
and MAS and in some instances rescue therapies the
same, ultimately the treatments for these diseases differ
significantly. For example, paediatric patients with
primary HLH require rescue therapy with high-dose cor-
ticosteroids, ciclosporin, etoposide, and ultimately allo-
geneic haematopoietic stem cell transplantation (HSCT)
[13]. Whilst these treatment approaches are required in
a minority of patients with MAS, usually high-dose cor-
ticosteroids, ciclosporin and treatment of the underlying
inflammatory disorder driving the MAS suffices [12].
Thus, distinguishing between primary HLH and MAS is
of utmost clinical importance in order to instigate ap-
propriate rescue therapy, provide prognostic informa-
tion, plan for allogeneic HSCT where required, and to
provide appropriate genetic counselling [14].
Currently the diagnosis of primary HLH is based on a
set of clinical and laboratory parameters that have been
developed and modified for use in therapeutic clinical
trials [15]. This diagnosis requires either a molecular
diagnosis (genetic confirmation), or 5/8 clinical criteria
(Table 1) being met. However, the specificity of these cri-
teria, particularly in differentiating primary from second-
ary HLH, is not well established. In addition, obtaining a
confirmatory definitive molecular diagnosis may take
several weeks or even months, and other genetic forms
of HLH are yet to be described [16]. Hence genetic con-
firmation of primary HLH is of limited value to guide
Fig. 1 Proteins screened in relation to pathways involved in pathogenesis of primary haemophagocytic lymphohistiocytosis (HLH). Cytotoxic T
lymphocytes and natural killer cells contain specialized secretory lysosomes - cytotoxic granules, which upon contact with a target-cell degranulate.
These granules contain perforin, a membrane-disrupting protein that facilitates the delivery of granzymes (proteases) that initiate apoptotic death in
target-cells. If perforin is deficient, it is suggestive of a diagnosis of Familial HLH type 2. To check the degranulation process, we can artificially activate
NK and CTL cells in the laboratory and measure using flow cytometry, a cell surface protein, CD107a (Granule Release Assay (GRA). If abnormal, it is an
indirect marker of a host of proteins which may be involved in the degranulation process - for example in trafficking, docking, priming for exocytosis,
or membrane fusion. An abnormal GRA may be suggestive of a diagnosis of familial HLH 3–5 or Griscelli, Chediak-Higashi or Hermansky-Pudlak. In boys
there are two X-Linked conditions, which result in protein deficiencies which can be screened for; SLAM – Associated Protein (SAP) which is important
in the killing of EBV infected cells – if deficient – suggestive of X linked Lymphoproliferative Disease ((XLP) type 1, and X Linked Inhibitor of Apoptosis
Protein (XIAP) which if deficient – suggestive of XLP type 2. XLP X linked lymphoproliferative disease type 1, XLP2 X linked lymphoproliferative disease
type 2, FHLH familial haemophagocytic lymphohistiocytosis, CTL cytotoxic T lymphocyte, NK natural killer
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clinical management in the acute setting [13]. Diagnostic
guidelines for MAS complicating sJIA and SLE exist
[17–20]. Although these guidelines may be helpful, they
have some limitations [21–23] including the fact that if
MAS is the main first presenting feature, the patients’
rheumatological diagnosis may still be unclear.
Increased understanding of the cell cytotoxic pathways
involved in the pathogenesis of primary HLH has led to
the development of a number of assays which may be
used to rapidly identify patients with primary HLH [24].
These include: flow cytometry–based protein screening
assays that quantify perforin; SLAM-associated protein
(SAP); X-linked inhibitor of apoptosis (XIAP) expres-
sion; and surface expression of CD107a, a surface lyso-
somal protein in cytotoxic granules used to quantify
degranulation in the cytotoxic cellular pathway (Fig. 1).
These screening tests have a quick return of results
(within 48 h) and can therefore help guide acute man-
agement since it is generally assumed that abnormal re-
sults are due to underlying genetic cause and hence
indicate primary forms of HLH [24]. However, given the
overlapping clinical features of primary HLH and MAS,
similar cytotoxic cellular pathways may also be involved
in the pathogenesis of MAS [25]. For instance natural
killer (NK) cell dysfunction is recognised in MAS com-
plicating systemic Juvenile Idiopathic Arthritis (sJIA)
[26, 27]. Reduced perforin expression has been observed
in patients with sJIA [28] and perforin gene mutations
and munc 13-4 polymorphisms have been linked to risk
of MAS in sJIA [29, 30]. However, the performance of
the aforementioned newer functional protein screening
assays in the evaluation of patients with MAS has not
yet been established.
We hypothesized that screening assays for primary
HLH could be relevant to children with MAS either by:
1. identifying those with potential primary genetic HLH;
and/or 2. defining a hitherto unrecognised subgroup of
MAS with poor prognosis. The aims of this study were
therefore to report the performance of these protein
screening assays in a cohort of children referred to our
tertiary paediatric rheumatology centre who underwent
investigative work up for MAS due to suspected but as
yet undetermined rheumatological cause. Specifically, we
wished to study any potential association between the
presence of any abnormal screening assay result, final
diagnosis, and outcomes including mortality or HSCT.
Methods
Study population
This was a 5-year retrospective review of children re-
ferred to paediatric rheumatology at Great Ormond
Street Hospital National Health Service Foundation
Trust between 1st January 2007 (when the CD107a
assay became routinely available at our institution) and
December 31st 2011. We included all patients who under-
went protein screening assays during this time period for
the work up of MAS due to suspected but as yet un-
defined rheumatological cause. Patients were identified
Table 1 Haemophagocytic Lymphohistiocytosis (HLH) 2004 clinical trial B diagnostic (clinical) criteria from 21 patients who had
investigative work up for macrophage activation syndrome at presentation and underwent protein-based and degranulation screening
tests for primary HLH from a single United Kingdom Paediatric Rheumatology centre
Number of
patients (%)
Number of patients
with information available
HLH diagnosis: B Criteria
Fever 19 (90) 21
Splenomegaly 9 (47) 19
Cytopenia (affected ≥2 of 3 lineages) 5 (24) 21
Haemoglobin <9 g/dl 11 (52)
(Infants <4 weeks: Haemoglobin <10 g/dl)
Platelets <100 × 109/l 7 (33)
Neutrophils <1 × 109/l 2 (1)
Hypertriglyceridaemia and/or hypofibrinogenaemia:
Fasting triglycerides ≥3 mmol/l 8 (53) 15
Fibrinogen ≤1.5 g/l 1 (0.1) 20
Haemophagocytosis in bone marrow or spleen or lymph nodes & no evidence of malignancy 7 (41) 17
Low or absent natural killer cell activity Not tested
Ferritin ≥500 μg/l 14 (74) 19
aSoluble CD25 ≥2400 U/ml 4 (100) 4
aOnly four patients had soluble CD25 levels tested. All were ≥2400 U/ml based on the original description of raised levels. It is acknowledged that >2SD from the
mean is thought to be more meaningful
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through a search of hospital based clinical and laboratory
databases. Data collected included: sex, ethnicity, age at
time of screening, disease duration, length of follow up,
presenting clinical features, and the frequency of HLH
2004 clinical diagnostic criteria parameters at time of
screening. Outcomes included final diagnosis, mortality or
HSCT. All blood samples were collected during the acute
presentation with active disease. Local research and devel-
opment approval was obtained for retrospective case
review (reference 12RUO1), and exemption from ethics
approval, under the Governance Arrangements for Re-
search Ethics Committee 2011, was granted.
Screening assays
Standard operating procedures for the granule release
assay and detection of perforin, XIAP and SAP are in-
cluded as a supplement [Additional file 1]. Cells were
permeabilised and stained as per Bryceson et al. [31]. In
brief whole blood samples (5–10 mL) were collected in
EDTA-containing vials. One healthy control sample was
processed in parallel to each patient sample.
For the granule release assay, peripheral blood mono-
nuclear cells were separated from whole blood and
stimulated overnight with IL-2. The cells were then
stimulated with PHA or anti-CD3 antibody in the pres-
ence of FITC anti-CD107a antibody for 2 h, then
stained with cell surface markers and analysed by flow
cytometry. An abnormal GRA result is when the in-
crease in %CD107a between stimulated and unstimu-
lated samples was <1.5 % for cytotoxic T cells after anti
CD3 stimulation and/or <15 % for NK cells after PHA
stimulation [32].
Whole blood intracellular FACs for SAP, XIAP and
perforin was performed by flow cytometry. Perforin is
abnormal if <50 % expression and/or fails to have the
brightest cells reach Mean Fluorescein Intensity of 103.
SAP and XIAP are abnormal if <50 % of cells express
SAP/XIAP.
Genetic analyses
Sanger sequencing of exons and exon/intron boundaries
was undertaken on all patients with abnormal protein
expression or degranulation. Primers and sequencing
conditions are available on request.
Statistical analyses
Fisher Exact Test was used to compare the outcome
between patient groups categorised based on the pres-
ence of an abnormal functional assay test. Continuous
variables were presented as median and range, and cat-
egorical data as percentages and proportions. SPSS version
18 was used for statistical analysis. P values of <0.05 were
considered significant.
Results
Patient demographics
Twenty-one patients (15 female) underwent screening
tests. Ethnicity included white British (11), Asian/Asian
British (3), black African/black British (4), Arab (1),
white other (2). Median age at time of screening was
6.5 years (range 0.6–16.0) and median disease duration
of 67 days (range 24 days– 6 years). One patient (an out-
lier) who had disease duration of 6 years was managed
at another hospital prior to having been referred to the
paediatric rheumatology service. Median follow-up was
16 months (range 1–51 months).
Clinical features and laboratory tests
Of the results available, only 3/21 (14 %) fulfilled a mini-
mum of 5/8 of the HLH -2004 (B) diagnostic clinical cri-
teria (Table 1). At presentation 19/21 (90 %) had fever;
12/20 (60 %) had hepatomegaly; 11/21 (52 %) had arth-
ritis; 9/19 (47 %) had splenomegaly; and 6/20 (30 %) had
evidence of central nervous system involvement (defined
as irritability, disorientation, headache, seizure or coma).
The median ferritin was 2531 (range 38–22076) μg/l;
median ESR 23 (range 3–160) mm/h; and median CRP
39 (range <5–187) mg/l. Table 2 summarises the clinical
and laboratory features for the patients with abnormal
screening results. Summary data set for each patient is
available [Additional file 2].
Protein and degranulation assay results
At least one screening test result was available for all 21
patients. Nineteen patients had the CD107a GRA per-
formed; for two patients the assays were technically in-
adequate to interpret. A total of 6/17 (35 %) had a
persistently abnormal GRA. A persistently abnormal
GRA was defined as a minimum of two abnormal GRA,
as per routine clinical practice). The median time
between first and second abnormal GRA was 27.5 days
(range 4 – 276 days). One boy had absent XIAP
expression. Nineteen patients had perforin screened,
and five male patients were screened for SAP expres-
sion; all had normal perforin and SAP results
respectively.
Final diagnoses
All seven patients with abnormal screening assays (six
with abnormal GRA, and one with absent expression of
XIAP) went on to have genetic testing for known muta-
tions associated with primary HLH. One patient with
absent expression of XIAP had subsequent genetic con-
firmation of XLP type 2 (c.1082C>G (p.Ser361X)). Only
1/6 patients with an abnormal GRA had positive genet-
ics (heterozygous UNC13 mutation as well as a second
heterozygous sequence variant, suggesting the diagnosis
of Familial HLH type 3); the remaining 5/6 patients with
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Table 2 Clinical and laboratory features of 7 patients referred with suspected macrophage activation syndrome who had abnormal screening results (GRA and XIAP)
Patient 3 4 5 6 7 8 18
Sex f f f m f f m
HLH 2004 B clinical criteria
Fever yes yes yes yes no yes yes
Splenomegaly yes / yes no no no yes
Cytopenia at least 2/3 yes no yes yes yes no yes
Hb <90 yes yes yes yes yes yes no
Plt <100 no no yes yes yes no yes
Neut <1 yes no no no no no yes
Hypertriglyceridemia
&/or hypofibrinogen
yes yes / no / yes /
Triglycerides >265 yes yes / no / yes /
Fibrinogen <1.5 no no no no no no no
Haemophagocytosis in bone
marrow, spleen or lymph nodes
no no / no yes yes /
Low or absent NK cell activity / / / / / / /
Ferritin >500 ng/ml yes yes yes yes yes yes no
Soluble CD25 >2400units/ml yes / / / / / /
Number of HLH B
clinical (2004)
6 3 4 3 3 4 3
Ferritin ng/ml 21065 1679 523 6759 2801 22076 38
ALT IU/L 17 17 12 453 6 354 102
Arthritis yes no no yes yes yes yes
ESR mm/h 100 10 78 20 18 120 6
CRP mg/L 48 74 60 / 51 87 6
Screening tests
GRA abnormal abnormal abnormal abnormal abnormal abnormal normal
SAP / / / normal / / normal
XIAP / / / normal / / absent
PERFORIN normal normal normal normal / normal normal
Genetics sent yes yes yes yes yes yes yes
Genetics no mutation
found
c.2335G>A/wt
and possible
deletion/splicing
defect
no mutation
found
no mutation
found
no mutation
found
no mutation
found
c.1082C>G
(p.Ser361X)
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Table 2 Clinical and laboratory features of 7 patients referred with suspected macrophage activation syndrome who had abnormal screening results (GRA and XIAP) (Continued)
Diagnosis sJIA primary HLH
(FHLH type 3)
primary HLH overlap syndrome
(JDM//SLE/sJIA)
SJIA SJIA primary HLH
(XLP2)
HSCT no no no no yes no yes
Survival alive deceased deceased alive alive alive alive
/= not done/no data available
HLH haemophagocytic lymphohistiocytosis, Hb haemoglobin, Plt platelets, Neut neutrophils, NK natural killer, AST aspartate aminotransferase, WCC white cell count, CNS central nervous system, SoJIA systemic onset
juvenile idiopathic arthritis, ALT alanine transaminase, ESR erythrocyte sedimentation rate, CRP C reactive protein, GRA granule release assay, SAP SLAM associated protein, XIAP X linked inhibitor of apoptosis protein,
HSCT haematopoietic stem cell transplantation, JDM juvenile dermatomyositis, SLE systemic lupus erythematosus, XLP2 X linked lymphoproliferative syndrome type 2
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abnormal GRA had no identifiable mutations in munc or
syntaxin genes. Their final diagnoses were: sJIA with MAS
(n = 3); primary HLH but without genetic confirmation
(n = 1); and overlap syndrome with features of juvenile
dermatomyositis, systemic lupus erythematosus and
sJIA (n = 1). The final diagnoses of the 11/17 patients
with normal GRA screening test abnormality are pro-
vided in Table 3.
Outcomes
Of the group of children with any persistent screening
test (GRA and XIAP) abnormality, 4/7 (57 %) either
died (2/7), or required HSCT (2/7), compared to 7 %
with no screening abnormality (none died, and 1/14
underwent HSCT); p = 0.025; Table 3. When data was
analysed specifically comparing outcome between ab-
normal and normal GRA it was not found to be statisti-
cally significant.
Discussion
In this study we report the use of protein-based and de-
granulation screening assays for primary HLH in a co-
hort of children referred to our tertiary paediatric
rheumatology centre with MAS due to suspected but as
yet undetermined rheumatological cause. We established
that these functional tests can direct genetic analyses
and may allow a rapid and reliable classification of pa-
tients, and are important prognostically. The presence of
persistently abnormal screening tests, defined a high risk
group with poor outcome (mortality or HSCT in 4/7
cases, 57 %). Although our data did not show a statistical
difference in outcome for patients when the data was
specifically analysed comparing those who had abnormal
and normal GRA tests, our numbers are small and it is
important still to highlight that 3/6 patients (50 %) who
had an abnormal GRA either died or required HSCT.
Overall 3/21 (14 %) of our patients who had protein-
based and degranulation screening tests were diagnosed
with primary HLH (two confirmed genetically, one clin-
ical diagnosis); novel molecular defects may be impli-
cated in the pathogenesis of HLH in the remaining cases
with abnormal GRA but negative routine genetic results.
To date, stratification of the mortality risk and/or the
need for urgent consideration of HSCT in patients pre-
senting with MAS has not been possible. Our findings,
albeit preliminary and retrospective, suggest for the
first time that a persistently abnormal CD107a de-
granulation screening assay may identify patients pre-
senting with MAS with poorer outcomes. Further
prospective multicentre studies are now needed to
validate this observation.
Our study focused on children in whom MAS was the
presenting feature and the remaining clinical manifesta-
tions were initially atypical for an established under-
lying inflammatory disease. As primary HLH and MAS
overlap clinically, we suggest that rapid screening for
primary HLH in these patients is warranted; however,
clinicians could consider these investigations for chil-
dren with MAS even with an established underlying
rheumatological disorder, particularly for those cases
not responding to high-dose corticosteroids and ciclos-
porin. Abnormal screening test findings could also de-
fine a high risk group in that context, and this remains
an area worthy of future study.
Table 3 Outcome - mortality or haematopoietic stem cell transplantation (HSCT) in relation to presence of protein based and
degranulation screening abnormalities in 21 patients with referred with suspected macrophage activation syndrome
Mortality or HSCT Alive and no HSCT Total P value
Abnormal screening test 4 3 7
CD107a GRA (persistently abnormal) Primary HLH n = 2 (1 UNC13D variant) sJIA n = 2
sJIA n = 1 Overlap syndrome (JDM/SLE/sJIA) n = 1
Absent XIAP Primary HLH (XLP2) n = 1 n = 0
Normal screening test 1 13 14 0.0253
Normal: sJIA n = 4
CD107a GRA sJIA n = 1 SLE n = 1
Perforin Streptococcal infection n = 1
XIAP Pancreatitis and SIRS n = 1
SAP Unclassified immunodeficiency n = 1
Langerhans Cell Histiocytosis n = 1
No clear diagnosis n = 4
Final diagnoses listed. Children with abnormal screening test results were more likely to die or undergo HSCT. p <0.05 by Fisher Exact Test was
considered significant
HLH haemophagocytic lymphohistiocytosis, GRA granule release assay, sJIA systemic juvenile idiopathic arthritis, JDM juvenile dermatomyositis, SLE systemic lupus
erythematosus, XIAP X linked inhibitor of apoptosis protein, XLP2 X linked lymphoproliferative syndrome type 2, SAP SLAM associated protein, SIRS systemic
inflammatory response syndrome
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Notably, three patients with sJIA and one patient
with overlap syndrome (with features of juvenile derm-
atomyositis, systemic lupus erythematosus and sJIA)
had a persistently abnormal CD107a test with negative
genetic tests (Table 3), suggesting that this assay is not
entirely specific for primary forms of HLH, and that
this pathway could be involved in the pathogenesis of
MAS in some patients. A recent study using whole-
exome sequencing in patients with systemic JIA and
MAS identified rare protein-altering variants in known
HLH-associated genes as well as in new candidate
genes [33]. This may be of relevance for our cohort.
Importantly, we have not yet examined the effect of
immunosuppressive treatment on this assay on this co-
hort of patients. However, in patients with primary
HLH treated with HLH-94 and HLH-2004 treatment
protocols, immunosuppressive therapy does not sig-
nificantly affect the degranulation assay result [31].
Previous studies have suggested temporary defects of
NK cell perforin expression in children with active sJIA
that normalises with successful treatment [16]. How-
ever, in our cohort of patients, perforin expression was
normal.
Our study is limited by all the confounding factors
associated with any retrospective case series, and we
acknowledge the small size and heterogeneity of this
cohort. In addition, there is a possibility that referral
bias resulted in us receiving the most severe cases of
secondary HLH/MAS. It is noted that perforin and
SAP assays were all normal in this cohort. Given the
small cohort size and rarity of primary HLH conditions
it would be incorrect to conclude from these findings
that they are not clinically helpful. As previously
mentioned, the longitudinal effect of immunosuppres-
sive treatment was not assessed, and requires further
investigation.
Conclusions
This study provides support that screening for primary
HLH is warranted for children whose first rheumato-
logical presentation is with MAS, since overall 14 % had
an eventual diagnosis of primary HLH. A persistently
abnormal GRA in patients presenting with MAS defines
a high-risk group with poor outcome (mortality or
HSCT), possibly due to as yet unidentified genetic cause.
Protein-based and degranulation screening assays may
therefore facilitate rapid identification of high risk
groups of patients referred to paediatric rheumatology
with MAS; we suggest these tests may be able to help
the clinician in those first few days to reach a diagnosis
of either primary HLH or MAS, and therefore may be
able to guide treatment decisions and improve prognosis
for this potentially fatal complication.
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